SEC Form POS AM filed by Bionomics Limited

$BNOX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $BNOX alert in real time by email
POS AM 1 ea0225664-posam_bionomics.htm POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-1

As filed with the Securities and Exchange Commission on December 23, 2024

Registration No. 333-280288

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

POST-EFFECTIVE AMENDMENT NO. 1 TO

FORM F-1 REGISTRATION STATEMENT NO. 333-280288

UNDER THE SECURITIES ACT OF 1933

 

Bionomics Limited

(Exact name of registrant as specified in its charter)

 

Not Applicable

(Translation of registrant’s name into English)

 

Australia   Not Applicable
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification Number)

 

200 Greenhill Road

Eastwood SA 5063

Australia

+618 8150 7400

(Address and telephone number of registrant’s principal executive offices)

 

Spyridon “Spyros” Papapetropoulos

President, Chief Executive Officer and Director

c/o Cogency Global Inc.

850 New Burton Road, Suite 201

Dover, DE 19904

(Name, address and telephone number of agent for service)

 

Copies to:

 

Andrew Reilly

Rimôn

Level 2, 50 Bridge Street
Sydney, NSW 2000, Australia

andrew.reilly@rimonlaw.com

 

Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this Registration Statement as determined in light of market conditions.

 

If only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

 

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.C. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐ 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.

 

Emerging growth company ☒

 

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 

 

 

 

 

EXPLANATORY NOTE

DEREGISTRATION OF SECURITIES

 

This Post-Effective Amendment No. 1 relates to the Registration Statement on Form F-1 (Registration No. 333-280288) filed by Bionomics Limited (the “Registrant”) with the Securities and Exchange Commission (“Commission”) on June 18, 2024 and as declared effective by the Commission on June 26, 2024 (the “Registration Statement”), registering up to 3,641,213,340 ordinary shares of the Registrant as represented by 20,228,963 American Depositary Shares (“ADSs”), all of which were initially issued by the Registrant pursuant to the Securities Purchase Agreement dated as of May 31, 2024 by and between the Registrant and the selling shareholder identified in the Registration Statement (the “Selling Shareholder”), as described therein.

 

On December 23, 2024 U.S. time (the “Effective Date”), the redomiciliation of the Registrant was completed pursuant to which Neuphoria Therapeutics Inc., a Delaware corporation (the “Company”), acquired all of the issued and outstanding ordinary shares of the Registrant in exchange for newly issued shares of common stock of the Company pursuant to a Scheme of Arrangement under Australian law (the “Scheme”), and became the ultimate parent company of the Bionomics group of companies. As a result of completion of the Scheme, the Company became the successor issuer to the Registrant pursuant to Rule 12g-3(a) under the Securities Exchange Act of 1934, as amended.

 

As a result of the Scheme, the Registrant has terminated all offerings of its securities pursuant to the Registration Statement. The Registrant, by filing this Post-Effective Amendment No. 1, hereby terminates the effectiveness of the Registration Statement and removes from registration any and all securities registered but unsold under the Registration Statement as of the date hereof. This filing is made in accordance with an undertaking in the Registration Statement to remove from registration by means of a post-effective amendment any of the securities that were registered but which remain unsold at the termination of the offering.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this post-effective amendment to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Boston, Massachusetts, on December 23, 2024.

 

  Bionomics Limited
     
  By: /s/ Spyridon Papapetropoulos
    Name:  Spyridon Papapetropoulos
    Title: President and Chief Executive Officer

 

No other person is required to sign this post-effective amendment in reliance upon Rule 478 under the Securities Act of 1933, as amended.

 

2

 

Get the next $BNOX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BNOX

DatePrice TargetRatingAnalyst
9/28/2023$7.00 → $10.00Buy
Maxim Group
9/28/2023$8.00Neutral → Buy
H.C. Wainwright
1/10/2022$54.00Buy
H.C. Wainwright
1/10/2022$52.00Overweight
Cantor Fitzgerald
1/10/2022$17.00Outperform
Evercore ISI Group
1/10/2022$21.00Buy
Berenberg
More analyst ratings

$BNOX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Bionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-Domiciliation

    ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company) is pleased to announce that the Supreme Court of New South Wales, Australia ("Court") has today made orders approving the scheme of arrangement in relation to the Company's proposed re-domiciliation from Australia to the United States ("Scheme"), under which Neuphoria Therapeutics Inc., a Delaware corporation ("Neuphoria"), will become the ultimate parent company of Bionomics Limited following the implementation of the Scheme. A copy of the Court's orders with respect to the Scheme was lodged with the Australian Securities & Investments Commission following t

    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Results of Scheme Meeting

    ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) ("Bionomics" or the "Company") is pleased to provide the following update on the status of its proposed re-domiciliation from Australia to the United States. Bionomics shareholders have today approved, by the requisite majority, the proposed Scheme of Arrangement in relation to the Company's proposed re-domiciliation from Australia to the United States, under which Neuphoria Therapeutics Inc., a Delaware corporation ("Neuphoria"), will become the ultimate parent company of Bionomics Limited following the implementation of the Scheme of Arrangement. Voting Results In summary: 96%

    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Bionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM Evidence

    BNC210 improved PTSD symptom severity at Week 12 with efficacy observed as early as Week 4Company plans to initiate a Phase 3 study of BNC210 in PTSD in H2 2025 ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that the positive results from its Phase 2 ATTUNE study have been published in the NEJM Evidence. The data were also presented yesterday at the 63ʳᵈ Annual Meeting of the

    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BNOX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BNOX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BNOX
SEC Filings

See more

$BNOX
Leadership Updates

Live Leadership Updates

See more
  • Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

    Alan Fisher appointed Chair of the Board of DirectorsTim Cunningham joins as Chief Financial Officer ADELAIDE, Australia and CAMBRIDGE, Mass., July 03, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO))) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced key leadership updates to drive its ongoing transformation to a U.S.-focused company, streamline its allocation of capital, and support its next stage of strategic growth. Alan Fisher, currently a non-executive me

    $BNOX
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Bionomics' Half-Year Report

    ADELAIDE, Australia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited ((ASX: BNO, NASDAQ:BNOX), today announced its FY2023 report for the half-year ended 31 December 2022. This period represented a transformational time for Bionomics in which the Company made great strides on multiple fronts, including progress on advancing the pipeline, raising capital, and implementing strategic corporate initiatives designed to create long-term shareholder value. The Company recently completed its Phase 2 PREVAIL Study to evaluate BNC210 for the acute treatment of Social Anxiety Disorder (SAD). The PREVAIL Study, initiated in January 2022, was a randomised, double-blind, placebo-controlled, multi-ce

    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Bionomics appoints Spyridon "Spyros" Papapetropoulos as President and Chief Executive Officer

    ADELAIDE, Australia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO))), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it has appointed Spyridon "Spyros" Papapetropoulos, M.D. as President and Chief Executive Officer (CEO), effective 5 January 2023. Errol B. De Souza, Ph.D., who has been serving as Bionomics' Executive Chairman since November 2018, will continue in his role through 31 December 2022 to ensure a seamless transition, and

    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BNOX
Financials

Live finance-specific insights

See more
  • Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder

    Successful End-of-Phase 2 (EoP2) meeting with U.S. Food and Drug Administration (FDA) provides a potential path to New Drug Application (NDA) submission for BNC210 for post-traumatic stress disorder (PTSD) with a single Phase 3 trialCompany received favorable FDA feedback on the Phase 3 study design and safety monitoring plans required for registrationCompany plans to initiate the Phase 3 program in Q4 2024A conference call and webcast presentation to discuss the outcomes will be held today at 8:00 a.m. ET, details below ADELAIDE, Australia and CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology com

    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024

    ADELAIDE, Australia and CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will provide a corporate update and discuss the outcomes of an end-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration regarding the advancement of BNC210 for the treatment of post-traumatic stress disorder (PTSD) into Phase 3 on Wednesday, July 31 at 8:00 am ET. Conference Call and Webcast PresentationDat

    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

    ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. Statistically significant secondary endpoints showed improvements in depressive symptoms and sleep. BNC210 was well-tolerated with a safety profile supporting chronic administration. Company plans to engage with the U.S. Food and Drug Administration (FDA) to discuss the registrational path for BNC210 in PTSD. Webcast and conference call will be held today at 8:00 AM EST (10:00 PM AEST). Please click on the link to register: https://lifescievents.com/event/bnox/ ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE)

    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BNOX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more